iBio Reports Q1 Loss, Shares Down 49.4% YTD
ByAinvest
Wednesday, Nov 12, 2025 6:27 pm ET1min read
IBIO--
iBio, Inc. reported a Q1 loss of $0.11 per share, exceeding the Zacks Consensus Estimate of a loss of $0.07. Revenues for the quarter ended September 2025 were $0.1 million, in line with the Zacks Consensus Estimate. The sustainability of the stock's immediate price movement will depend on management's commentary on the earnings call. The company has underperformed the market so far this year, with shares down 49.4% versus the S&P 500's gain of 16.4%. The Zacks Rank for the stock is #3 (Hold).
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet